Quanterix non-invasive blood test for detection of Phosphorylated Tau-181
The recent emergence of promising new candidate Alzheimer’s therapies has brought to light an urgent need to facilitate the diagnosis of the disease in its early stages when therapeutic intervention is most likely to deliver clinical benefit. While Alzheimer’s disease diagnostics often relies on a clinically based diagnoses of exclusion, biomarkers are playing an increasingly important role in the diagnostic journey. The Quanterix pTau-181 test has shown clinical validity as a new diagnostic tool for identifying early symptomatic individuals at risk of being on a path of Alzheimer’s disease. Download the whitepaper to learn more.
Share this page